Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cue Biopharma, Inc. CUE NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
60/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$4.33
+888.6%

Cue Biopharma, Inc. (CUE) is a Biotechnology company in the Healthcare sector, currently trading at $0.44. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is CUE = $4 (+888.6% upside).

Valuation: CUE trades at a trailing Price-to-Earnings (P/E) of -1 (S&P 500 average ~25).

Financials: revenue is $27M, +201.9%/yr average growth. Net income is $27M (loss), growing at +19.4%/yr. Net profit margin is -96.9% (negative). Gross margin is 87.3% (+132.3 pp trend).

Balance sheet: total debt is $4M against $26M equity (Debt-to-Equity (D/E) ratio 0.16, conservative). Current ratio is 2.74 (strong liquidity). Debt-to-assets is 9.9%. Total assets: $42M.

Analyst outlook: 9 / 9 analysts rate CUE as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

$4.33
▲ 888.58% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Cue Biopharma, Inc., the average price target is $4.33, with a high forecast of $7.00, and a low forecast of $2.00.
Highest Price Target
$7.00
Average Price Target
$4.33
Lowest Price Target
$2.00

CUE SharesGrow Score Overview

70/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 90/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CUE

✓
VALUE Pass
100/100
CUE trades at a trailing Price-to-Earnings (P/E) of -1 (S&P 500 average ~25). Forward PEG -0.29 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $4, implying +813.2% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
90/100
CUE: +201.9%/yr revenue is, +19.4%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet CUE: Debt-to-Equity (D/E) ratio 0.16 (conservative), Current ratio is 2.74 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
CUE: Gross margin is 87.3% (+132.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 9 / 9 analysts rate CUE as buy (100%). Analyst consensus target is $4 (+813.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
CUE: Net profit margin is -96.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.174-1.03
Volume7.27M
Avg Volume (30D)7.67M
Market Cap$34.53M
Beta (1Y)1.58
Share Statistics
EPS (TTM)-0.28
Shares Outstanding$94.73M
IPO Date2018-01-02
Employees41
CEOColin G. Sandercock
Financial Highlights & Ratios
Revenue (TTM)$27.47M
Gross Profit$23.99M
EBITDA$-23.04M
Net Income$-26.6M
Operating Income$-26.55M
Total Cash$27.14M
Total Debt$4.2M
Net Debt$-22.94M
Total Assets$42.21M
Price / Earnings (P/E)-1.6
Price / Sales (P/S)1.26
Analyst Forecast
1Y Price Target$4.00
Target High$7.00
Target Low$2.00
Upside+813.2%
Rating ConsensusBuy
Analysts Covering9
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS22978P1066

Price Chart

Track all markets on TradingView
CUE
Cue Biopharma, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.17 52WK RANGE 1.03

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 FENC
FENC
Fennec Pharmaceuticals Inc.
$6.25
+5.40%
 ANIX
ANIX
Anixa Biosciences, Inc.
$2.88
+1.05%
 COYA
COYA
Coya Therapeutics, Inc.
$4.46
+0.22%
 CGTX
CGTX
Cognition Therapeutics, Inc.
$0.98
+0.10%
 TCRX
TCRX
TScan Therapeutics, Inc.
$1.06
+3.92%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message